3 unchanged sentences
ADMA Biologics, Inc.
+Added: August 9, 2023
President and Chief Executive Officer
+Added: August 9, 2023
/s/ Brian Lenz
2 unchanged sentences
Exhibit Number
−Removed: Form of Warrant (incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K filed with the SEC on May 2, 2023).
−Removed: Amendment No.
−Removed: 1 to Credit Agreement and Guaranty, dated March 22, 2023, by and among the Company, Hayfin Services LLP and the lenders party thereto (incorporated by reference to Exhibit 10.25.1 of the Company’s
−Removed: Annual Report on Form 10-K filed with the SEC on March 23, 2023).
−Removed: Amendment No.
−Removed: 2 to the Credit and Guaranty Agreement, dated as of May 1, 2023, by and among the Company, Hayfin Services LLP and the lenders party thereto (incorporated by reference to Exhibit 10.1 of the
−Removed: Company’s Current Report on Form 8-K filed with the SEC on May 2, 2023).
Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
2 unchanged sentences
Certification of Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: The following materials from ADMA Biologics, Inc.’s Form 10-Q for the quarter ended March 31 2023, formatted in Extensible Business Reporting Language (XBRL):
−Removed: (i) Condensed Consolidated Balance Sheets as of March
−Removed: 31, 2023 (Unaudited) and December 31, 2022, (ii) Condensed Consolidated Statements of Operations (Unaudited) for the three months ended March 31, 2023 and 2022, (iii) Condensed Consolidated Statements of Changes in Stockholders’ Equity
−Removed: (Unaudited) for the three months ended March 31, 2023 and 2022, (iv) Condensed Consolidated Statements of Cash Flows (Unaudited) for the three months ended March 31, 2023 and 2022, and (v) Notes to (Unaudited) Condensed Consolidated
−Removed: Financial Statements.
+Added: The following materials from ADMA Biologics, Inc.’s Form 10-Q for the quarter ended June 30 2023, formatted in Extensible Business Reporting Language (XBRL):
+Added: (i) Condensed Consolidated Balance
+Added: Sheets as of June 30, 2023 (Unaudited) and December 31, 2022, (ii) Condensed Consolidated Statements of Operations (Unaudited) for the three months and six months ended June 30, 2023 and 2022, (iii) Condensed Consolidated
+Added: Statements of Changes in Stockholders' Equity (Unaudited) for the three and six months ended June 30, 2023 and 2022, (iv) Condensed Consolidated Statements of Cash Flows (Unaudited) for the six months ended June 30, 2023 and 2022,
+Added: and (v) Notes to (Unaudited) Condensed Consolidated Financial Statements.
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.